KEYNOTE-B21: Pembrolizumab Plus Adjuvant Chemotherapy in High-Risk Endometrial Cancer Last updated on Jun 8, 2026 Previous HIPEC in ovarian cancer Next Keynote B21 - Pembrolizumab in High-Risk Endometrial Cancer (Video Explainer)
